Recognizing misleading pharmaceutical marketing online.

J Am Acad Psychiatry Law

Mr. De Frietas is a Research Candidate in Experimental Psychology, Department of Experimental Psychology, Oxford University, Oxford, UK. Dr. Falls is a member of the Program in Psychiatry and the Law and a Clinical Fellow in Psychiatry, Department of Psychiatry, Harvard Medical School, Department of Psychiatry, VA Boston Healthcare System, Boston, MA. Dr. Haque is a member of the Program in Psychiatry and the Law, Harvard Medical School, Department of Psychiatry at the Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Cambridge, MA, and a Resident, Department of Psychiatry and Human Behavior, Brown University, Providence, RI. Dr. Bursztajn is Associate Clinical Professor and Co-Founder, Program in Psychiatry and the Law Harvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical Center and the Massachusetts Mental Health Center, Cambridge, MA.

Published: March 2015

AI Article Synopsis

  • The article examines how drug marketing functions in both traditional and new online spaces, highlighting trends that lead to misleading prescribing practices and patient requests for medications.
  • The rise of the Internet has amplified pharmaceutical marketing, making it more prominent and potentially misleading, particularly in the field of psychiatry where psychotropic medications are highly profitable.
  • The authors suggest that enhancing independent oversight and raising consumer awareness about online pharmaceutical marketing can help combat these misleading practices.

Article Abstract

In light of decision-making psychology, this article details how drug marketing operates across established and novel web domains and identifies some common misleading trends and influences on prescribing and patient-initiated medication requests. The Internet has allowed pharmaceutical marketing to become more salient than ever before. Although the Internet's growth has improved the dissemination of pharmaceutical information, it has also led to the increased influence of misleading pharmaceutical marketing. Such mismarketing is of concern, especially in psychiatry, since psychotropics generate considerable revenue for drug companies. In a climate of resource-limited drug regulation and time-strapped physicians, we recommend improving both independent monitoring and consumer awareness of Internet-enabled, potentially misleading, pharmaceutical marketing influences.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pharmaceutical marketing
16
misleading pharmaceutical
12
pharmaceutical
5
marketing
5
recognizing misleading
4
marketing online
4
online light
4
light decision-making
4
decision-making psychology
4
psychology article
4

Similar Publications

Drug-Silica-Cellulose Ternary Matrix for the Oral Delivery of Cyclosporine A: and evaluation.

Pharm Dev Technol

January 2025

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhavnagar, Manipal - 576104, Karnataka, India.

Purpose: Supersaturated formulations have been widely explored for improving the oral bioavailability of drugs by using mesoporous silica (MS) to generate supersaturation via molecular adsorption; however, this is followed by precipitation. Several precipitation inhibitors (PI) have been explored to prevent precipitation and maintain the drug in solution for a longer period. However, the combined approach of MS and PIs, the impact of MS and Silica, and the loading of high-molecular-weight neutral molecules such as Cyclosporine A (CsA) have not yet been explored.

View Article and Find Full Text PDF

Surveillance of drug prescribing: why outliers miss their targets - a qualitative study.

BMC Health Serv Res

January 2025

Institute of General Practice/Family Medicine, Philipps-University of Marburg, Karl-Von-Frisch-Straße 4, 35043, Marburg, Germany.

Background: Rising costs are a challenge for healthcare systems. To keep expenditure for drugs under control, in many healthcare systems, drug prescribing is continuously monitored. The Bavarian Drug Agreement (German: Wirkstoffvereinbarung or WSV) for the ambulatory sector in Bavaria (the federal state of Germany) was developed for this purpose.

View Article and Find Full Text PDF

Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder.

Biomaterials

December 2024

Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Ophthalmology, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA, 23298, USA; Center for Pharmaceutical Engineering, Center for Drug Discovery, Department of Pediatrics, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA. Electronic address:

The opioid crisis has claimed approximately one million lives in the United States since 1999, underscoring a significant public health concern. This surge in opioid use disorder (OUD) fatalities necessitates improved therapeutic options. Current OUD therapies often require daily clinical visits, leading to poor patient compliance and high costs to the health systems.

View Article and Find Full Text PDF

Cardiac pathology associated with hypertension and chronic kidney disease in aged cats.

J Comp Pathol

January 2025

Department of Comparative Biomedical Sciences, Royal Veterinary College, University of London, Royal College Street, London NW1 0TU, UK. Electronic address:

Hypertension is a common condition in older cats, often secondary to chronic kidney disease (CKD). Although the heart is one of the organs damaged by hypertension, the pathology of the feline hypertensive (HT) heart has been poorly studied. The aim of this retrospective study was to describe the gross and microscopic pathology of hearts obtained from cats at post-mortem examination and to compare cats diagnosed with hypertension with cats of similar age and kidney function for which antihypertensive treatment was not deemed clinically necessary.

View Article and Find Full Text PDF
Article Synopsis
  • Centralized drug procurement, like China's 2018 CVBP, aims to ease healthcare costs and enhance the pharmaceutical industry.
  • Research on the impact of this procurement method shows it significantly boosts R&D investment among pharmaceutical firms, especially those with high marketing expenses.
  • The study utilizes data from listed firms in China's A-share market, confirming the findings through various robust testing methods, thus offering valuable insights for governments and firms on fostering innovation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!